Evidence map›Paper›PMID 27828963›Full record

ArticlePLoS genetics2016

Proteomic Landscape of Tissue-Specific Cyclin E Functions in Vivo.

Junko Odajima, Siddharth Saini, Piotr Jung, Yasmine Ndassa-Colday, Scott Ficaro, Yan Geng, Eugenio Marco, Wojciech Michowski, Yaoyu E Wang, James A DeCaprio and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Emerging Role of the DREAM Complex in Cancer and Therapeutic Opportunities.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability.Frontiers in cell and developmental biology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Junko OdajimaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Siddharth SainiDepartment of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.ORCID http://orcid.org/0000-0002-2813-9536
Piotr JungDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Yasmine Ndassa-ColdayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Scott FicaroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Yan GengDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Eugenio MarcoDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Wojciech MichowskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Yaoyu E WangCenter for Cancer Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
James A DeCaprioDepartment of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
Larisa LitovchickDepartment of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Jarrod MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Piotr SicinskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Harvard University · USDana-Farber Cancer Institute · USVirginia Commonwealth University · US

Funding

Tumor Cell Biology Training ProgramT32CA009361 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, NATHANAEL SCHIANDER · 1985 to 2015
$8.9M
PROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0M
RB-RELATED PROTEINS IN SV4OT AND E1A TRANSFORMATIONR01CA063113 · NCI · DANA-FARBER CANCER INSTITUTE · PI DECAPRIO, JAMES A. · 1994 to 2018
$5.0M
SPECIFIC ROLES FOR D-CYCLINS IN ONCOGENESISR01CA083688 · NCI · DANA-FARBER CANCER INSTITUTE · PI SICINSKI, PETER · 2000 to 2016
$4.6M
Novel functions of D-type and E-type cyclins in normal and in cancer cellsR01CA202634 · NCI · DANA-FARBER CANCER INST · PI SICINSKI, PETER · 2016 to 2020
$2.1M
DYRK1A signaling in control of cell growth, proliferation and DNA damage repairR01CA188571 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LITOVCHICK, LARISA · 2015 to 2019
$2.0M
NCI NIH HHS P01 CA203655NCI NIH HHS R01 CA063113NCI NIH HHS R01 CA083688NCI NIH HHS R01 CA188571NCI NIH HHS R01 CA202634NCI NIH HHS T32 CA009361
6 · The paper itself

Abstract

E-type cyclins (cyclins E1 and E2) are components of the cell cycle machinery that has been conserved from yeast to humans. The major function of E-type cyclins is to drive cell division. It is unknown whether in addition to their 'core' cell cycle functions, E-type cyclins also perform unique tissue-specific roles. Here, we applied high-throughput mass spectrometric analyses of mouse organs to define the repertoire of cyclin E protein partners in vivo. We found that cyclin E interacts with distinct sets of proteins in different compartments. These cyclin E interactors are highly enriched for phosphorylation targets of cyclin E and its catalytic partner, the cyclin-dependent kinase 2 (Cdk2). Among cyclin E interactors we identified several novel tissue-specific substrates of cyclin E-Cdk2 kinase. In proliferating compartments, cyclin E-Cdk2 phosphorylates Lin proteins within the DREAM complex. In the testes, cyclin E-Cdk2 phosphorylates Mybl1 and Dmrtc2, two meiotic transcription factors that represent key regulators of spermatogenesis. In embryonic and adult brains cyclin E interacts with proteins involved in neurogenesis, while in adult brains also with proteins regulating microtubule-based processes and microtubule cytoskeleton. We also used quantitative proteomics to demonstrate re-wiring of the cyclin E interactome upon ablation of Cdk2. This approach can be used to study how protein interactome changes during development or in any pathological state such as aging or cancer.

Indexed as

ProteomicsAnimalsCell CycleCell ProliferationCyclin-Dependent Kinase 2Cyclin ECyclinsHumansMaleMiceOncogene ProteinsPhosphorylationProtein Interaction MapsSpermatogenesisS PhaseTestisCcne2 protein, mouseCdk2 protein, mouseCyclin-Dependent Kinase 2Cyclin Ecyclin E1, mouseCyclinsOncogene Proteins

Identifiers

PMID27828963
PMCPMC5102403
OpenAlexW2555526827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.